
BioNTech SE (BNTX) Stock Forecast & Price Target
BioNTech SE (BNTX) Analyst Ratings
Bulls say
BioNTech reported a robust cash position of approximately €16.7 billion at the end of Q3 2025, indicating strong financial stability and the capacity to fund ongoing research and development initiatives. The company's promising clinical pipeline, notably the global Phase 3 DYNASTY-Breast02 trial evaluating BNT323, suggests potential advancements in its oncology portfolio that could drive future revenue growth. Additionally, the development of an advanced COVID-19 vaccine that elicits improved immune responses against various sublineages reinforces BioNTech's commitment to innovation and addresses ongoing public health needs, positioning the company favorably in the biotechnology market.
Bears say
BioNTech faces significant financial challenges, including a projected full-year net loss per diluted share of €3.99 for 2025, following a net loss of €0.12 per diluted share for the third quarter of 2025. The company is also exposed to various risks that could hinder its performance, such as negative clinical trial data for several key oncology programs, slower-than-expected market uptake of its products, and potential regulatory and commercial issues. Furthermore, the ongoing volatility in the COVID-19 vaccine market, especially due to increased restrictions in the U.S., may divert investor attention from BioNTech's oncology initiatives, compounding the financial strain.
This aggregate rating is based on analysts' research of BioNTech SE and is not a guaranteed prediction by Public.com or investment advice.
BioNTech SE (BNTX) Analyst Forecast & Price Prediction
Start investing in BioNTech SE (BNTX)
Order type
Buy in
Order amount
Est. shares
0 shares